Fc-GLP-1 also improved the fatty liver phenotype in DIO mice, confirming the efficacy of this GLP-1R agonist in obese and non-obese hepatic dysfunction linked to NAFLD. This evidence concerns the gene GCG and metabolic dysfunction-associated steatotic liver disease.